leisure time -WSS

leisure time

author：knowledge 2025-08-30 19:15:49 - browse：265

Three Wegovy injection pens in a row — first opinion coverage from STAT — Adobe

Novo Nordisk will test whether its GLP-1 drugs can help people with alcohol-associated liver disease, and, as part of that, will study if the treatments will change the amount of alcohol people drink.

This appears to be the first time the company is getting involved in research to see if the booming class of GLP-1 diabetes and obesity drugs can affect substance consumption, a question that academic researchers have been probing but the pharmaceutical industry has so far avoided.

The nine-month study will try three drugs alone and in combinations against placebo. The primary outcome being tested is change in liver scarring, or fibrosis, and one of the secondary outcomes is changes in alcohol consumption. The news of the study was first reported by Bloomberg.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Health tech investors get more selective as pandemic boom fades

WSS

Neuroscience’s long legacy of racism

5 to watch: Tech startups trying to solve health care's staffing crisis

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Why a market frenzy over new weight loss drugs defies logic

Gene editing the human germline: What are the risks?

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

leisure time

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Peter Hotez and the public health issue of online harassment

Creating egg and sperm cells from stem cells raises ethical issues

Trump demands the U.S. pay no more for drugs than other countries … again

STAT Summit: Meghan O’Rourke on making chronic illness visible

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

entertainment

Roche drug slashes death risk in early

Baby aspirin cuts fat buildup in liver disease patients, in small study

Why a market frenzy over new weight loss drugs defies logic

Roche acquires Telavant from Roivant, adding experimental IBD treatment

SCOTUS questions limit to govt efforts to fight misinformation

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Wikipedia

hotspot

focus

hotspot